Enters Collaboration with Boston Academic Teaching Hospital to Expand Preclinical Data in Type 1 Diabetes
Boston, July 30, 2013 AEST (ABN Newswire) - Medistem, Inc. (
MEDS:OTCMKTS), announced today it has entered into collaboration with Reza Abdi, M.D., Transplant Nephrologist at Brigham and Women's Hospital and Assistant Professor of Medicine, Harvard Medical School. Under the collaboration, the Company will provide Dr. Abdi with its Endometrial Regenerative Cells (ERCs) and it is expected that his research would support FDA clearance to initiate clinical trials to use ERCs as a treatment for Type 1 Diabetes. Currently, the Company has FDA clearance to initiate a dose-escalating Phase I clinical trial to use ERCs in patients with critical limb ischemia, a complication of diabetes.
"Currently there are no treatments that reverse Type 1 diabetes. ERCs have a great potential to emerge as a cell therapy for type 1 diabetes by blocking the pathological autoimmune process that is causative of the disease," said Dr. Abdi.
"An independent study conducted by the National Institutes of Health (NIH), has shown that our ERCs posses superior ability to modulate immune response as compared to other types of stem cells," furthermore "In previous studies, ERCs have shown the ability to produce chemical signals that inhibit autoimmune conditions such as Type 1 diabetes and multiple sclerosis." said Alan J. Lewis, Ph.D., Chief Executive Officer of Medistem. "We are delighted to be working with Dr. Abdi as we believe this collaboration could lead to a breakthrough in the treatment of Type 1 Diabetes."
Contact
Phone: +1-858-352-7071
E-mail: info@medisteminc.com
www.medisteminc.com
| ||
|
